Today, most of the COVID-19 vaccine containers are vials, thanks to their flexibility in the drug development phase and their possibility of delivering multi-doses with a single container.
However, even without considering the impact of COVID-19, the demand for vaccines in syringes is expected to grow. Due to the several benefits, such as reducing medical dosing errors, minimizing the risk of contamination by the ease of use, and reducing waste of drug products, syringes will represent a win-win scenario for end-users and manufacturers.
When converting from a vial delivery method to a pre-fillable syringe, we need to consider several factors: indeed, every vaccine has unique features requiring different packaging characteristics in terms of sensitivity to temperature, the scale of manufacture, and delivery technology.
In this webinar, we provided an overview of the strategy to speed up the migration from a vial to a pre-fillable syringe to address all these aspects. We discussed the different packaging characteristics, assess the syringe platform, and present what Stevanato Group can offer to support pharma partners in delivering a safe and effective vaccine.
Specifically, the focus is to illustrate:
Enrico Barichello - Product Manager, Stevanato Group
Professionals involved in, development, and manufacturing of biopharmaceuticals, primary drug container and parenteral drug device development like:
Product Manager, Stevanato Group
With a background in Industrial Engineering and a Master’s in Management at the University of Padua, Enrico Barichello acquired broad-spectrum skills in technical concepts and complex processes.
He joined Stevanato Group in 2017 as a Product Management Specialist for syringe platform. He defined and coordinated all the activities required to bring the products to market, bridging gaps between different company functions and aligning the involved teams.
From January 2021, he is the product owner, responsible for the roadmap and execution of the new innovative platform SG Alba®.